Health Care Archives - Page 31 of 478

2 minute read

Rising Cost For Health Insurers Bites CVS Health’s Q1 Profit, Stock Tanks

May 1, 8:52 AM

CVS Health Q1 sales of $88.4 billion, up 3.7% Y/Y. Adjusted EPS at $1.31, down from $2.20. Health Care Benefits segment sees strong growth, while Health Services segment faces challenges. Revised 2024 guidance reflects continued pressure on earnings.

CVS

2 minute read

April Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy Market

By Piero Cingari

April 30, 4:38 PM

Performance in April 2024: Utilities lead, real estate lags. S&P 500, Nasdaq 100, Dow Jones Industrial Average, small-cap and large-cap indices all decline.

AAUKF

2 minute read

Americans Swap $5 Burgers For $1,000 Weight Loss Drugs — Is Soda Getting Left Behind Too?

By Aaron Bry

April 30, 3:22 PM

Weight-loss drugs may be impacting fast-food sales, as Eli Lilly beats estimates and raises revenue guidance while McDonald's and Coca-Cola report underwhelming quarters.

2 minute read

Goldman Scrutinizes Hits, Misses, And Growth Trajectory Concerns For Eli Lilly And Its Its Obesity and Diabetes Drugs

By Vandana Singh

April 30, 3:11 PM

Eli Lilly boosts production for obesity and diabetes drugs, reports mixed Q1 results. Expectations for supply growth in 2024 outlined. Insights into payor access and reimbursement strategies discussed.

LLY

2 minute read

Walmart to Shut Down All Clinic Locations Amid Rising Costs – What It Means for Your Healthcare?

By Vandana Singh

April 30, 1:17 PM

Walmart to close healthcare clinics nationwide. 51 clinic locations shutting down, pharmacies and vision centers remain open. Company cites challenging reimbursement environment and rising operating costs.

WMT

2 minute read

Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab

By Vandana Singh

April 30, 11:54 AM

Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost.

AMGN

2 minute read

Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View

By Vandana Singh

April 30, 11:44 AM

Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with adjusted EPS surpassing expectations.

HRMY

2 minute read

GE HealthCare’s Q1 Earnings Miss Wall Street Projections, But It Sticks To Annual Guidance

By Vandana Singh

April 30, 11:31 AM

GE Healthcare reports first-quarter sales of $4.6 billion, with net income of $374 million. Imaging and ultrasound segment revenues down, but pharmaceutical diagnostics up. Despite challenges in China, CEO remains optimistic, reaffirming guidance for 2024.

GEHC

2 minute read

Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings

By Surbhi Jain

April 30, 11:18 AM

Pfizer's Q1 earnings report expects EPS of 49 cents and $13.09 billion in revenues. Stock has declined 34.61% YoY and -10.94% YTD due to COVID-19 revenue decrease. Technical analysis shows bearish trend with potential for further downside.

PFE

2 minute read

Why Is Hospital Chain Operator Tenet Healthcare Stock Soaring On Tuesday?

By Vandana Singh

April 30, 10:53 AM

Discover Tenet Healthcare's robust first-quarter performance, boasting $5.37 billion in sales, a 7% Y/Y increase. With strong revenue growth, admissions, and profitability, Tenet is raising its fiscal year 2024 revenue guidance to $20-$20.4 billion.

THC